Immune checkpoint blockade reveals the stimulatory capacity of tumor-associated CD103(+) dendritic cells in late-stage ovarian cancer.
about
Trial watch: Immune checkpoint blockers for cancer therapy.Phagocyte-extracellular matrix crosstalk empowers tumor development and dissemination.Targeting LAG-3 and PD-1 to Enhance T Cell Activation by Antigen-Presenting Cells.Trial watch: Dendritic cell-based anticancer immunotherapy.Recent advances in understanding dendritic cell development, classification, and phenotypeOvarian Tumor Microenvironment Signaling: Convergence on the Rac1 GTPase
P2860
Immune checkpoint blockade reveals the stimulatory capacity of tumor-associated CD103(+) dendritic cells in late-stage ovarian cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 13 May 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Immune checkpoint blockade reveals the stimulatory capacity of tumor-associated CD103
@nl
Immune checkpoint blockade rev ...... in late-stage ovarian cancer.
@en
type
label
Immune checkpoint blockade reveals the stimulatory capacity of tumor-associated CD103
@nl
Immune checkpoint blockade rev ...... in late-stage ovarian cancer.
@en
prefLabel
Immune checkpoint blockade reveals the stimulatory capacity of tumor-associated CD103
@nl
Immune checkpoint blockade rev ...... in late-stage ovarian cancer.
@en
P2093
P2860
P1433
P1476
Immune checkpoint blockade rev ...... in late-stage ovarian cancer.
@en
P2093
Dallas B Flies
Jaryse C Harris
Phyllis A Gimotty
Sarah F Adams
Tomoe Higuchi
P2860
P304
P356
10.1080/2162402X.2016.1185583
P577
2016-05-13T00:00:00Z